Cargando…
Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study
ABSTRACT: BACKGROUND: Lanthanum carbonate (FOSRENOL(®)) is an effective, well-tolerated phosphate binder. The ability of lanthanum to reduce serum phosphorus levels to ≤5.5 mg/dL in patients with end-stage renal disease (ESRD) was assessed in a clinical practice setting. METHODS: A 16-week, phase IV...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197476/ https://www.ncbi.nlm.nih.gov/pubmed/21962172 http://dx.doi.org/10.1186/1471-2369-12-49 |